Cumulus Neuroscience (Cumulus, The Company), a leading global innovator providing real-world clinical trial data and AI-powered insights to accelerate the development of life-changing CNS therapies, announces that Dr Ruth McKernan CBE, a Founder, and Director of the company, has been appointed as Chair.
Dr. McKernan, neuroscientist, is a Venture Partner at the Dementia Discovery Fund (DDF), a specialist venture capital fund managed by SV Health Investors, where she has been involved in co-founding DDF companies Loqus23 and AstronauTX. Immediately prior to joining DDF, she spent three years as CEO of the UK Government’s Innovation agency, InnovateUK, and played a key role in creating the Industrial Strategy Challenge and supporting Technology centers and SMEs.
Ruth has 25 years of research and development experience in the pharmaceutical industry, including heading up research units in the UK and the US. Ruth’s previous roles include Senior Vice President at Pfizer and Head of the Merck Neuroscience Research Centre. She has been a member of the Medical Research Council, Cancer Research UK and is a trustee at Alzheimer’s Research UK. Ruth is an active and enthusiastic entrepreneur who currently chairs the UK BioIndustry Association and adds Cumulus to her other Board roles at Cerevel and AstronauTx.
Ruth’s awards and achievements include a CBE in 2013 for services to Business, Innovation and Skills, a Fulbright Scholarship, and a Glaxo/ABSW Science Writers’ Award. Ruth is the author of more than 120 scientific papers and 15 patents as well as a book for non-scientists, “Billy’s Halo”.
Cumulus Neuroscience CEO Ronan Cunningham commented: “We are delighted that Ruth has agreed to become Chair of Cumulus Neuroscience. She has played an instrumental role in the founding and early development of the company, helping to bring together the suite of technologies that enable our integrated platform. Her considerable experience and broad knowledge of the field will be invaluable in the further development and clinical application of our technology.”
Ruth McKernan, newly appointed Chair added: “The formation of Cumulus Neuroscience represents a significant opportunity to address some of the current limitations of clinical trials in dementia and other brain disorders. There are many new therapeutics for dementia now in research and clinical studies. A broad-based fully integrated platform that accurately reports disease progression will accelerate getting those medicines to patients. I look forward to continuing to work with Cumulus – it is an exciting new company with wonderful ambition.”